EBQ:Thrombolysis in Pulmonary Embolism Metanalysis - Revision history

Danbot: Added funding information

2026-03-21T22:35:10Z

Added funding information

← Older revision		Revision as of 22:35, 21 March 2026
Line 67:		Line 67:
	==Funding==		==Funding==


			*None reported (meta-analysis)

	==Sources==		==Sources==

Danbot: Mark as Complete - article has all required sections

2026-03-21T22:11:23Z

Mark as Complete - article has all required sections

← Older revision		Revision as of 22:11, 21 March 2026
Line 13:		Line 13:
	\| fulltexturl= http://unmhospitalist.pbworks.com/w/file/fetch/82297066/joi140068.pdf		\| fulltexturl= http://unmhospitalist.pbworks.com/w/file/fetch/82297066/joi140068.pdf
	\| pdfurl=http://unmhospitalist.pbworks.com/w/file/fetch/82297066/joi140068.pdf		\| pdfurl=http://unmhospitalist.pbworks.com/w/file/fetch/82297066/joi140068.pdf
			\| status = Complete
	}}		}}
	==Clinical Question==		==Clinical Question==

Rossdonaldson1: /* Criticisms & Further Discussion */

2018-12-18T19:16:40Z

Criticisms & Further Discussion

← Older revision		Revision as of 19:16, 18 December 2018
Line 55:		Line 55:

	==Criticisms & Further Discussion==		==Criticisms & Further Discussion==
	#There are still very few patients (n=2115) included in RCT assessing impact of thrombolysis in PE to conclude with assurance about benefit or harm. Need exists for adequately powered study.		*There are still very few patients (n=2115) included in RCT assessing impact of thrombolysis in PE to conclude with assurance about benefit or harm. Need exists for adequately powered study.
	#There is only one study (ULTIMA) having analyzed the effect of catheter-delivered thrombolysis via a pulmonary artery catheter and results of this review should only be applied to systemic thrombolysis.		*There is only one study (ULTIMA) having analyzed the effect of catheter-delivered thrombolysis via a pulmonary artery catheter and results of this review should only be applied to systemic thrombolysis.

	==External Links==		==External Links==

Rossdonaldson1: /* Outcomes */

2018-12-18T19:16:25Z

Outcomes

Rossdonaldson1 at 19:11, 18 December 2018

2018-12-18T19:11:40Z

← Older revision		Revision as of 19:11, 18 December 2018
Line 48:		Line 48:
	#Major bleeding was not significantly increased in pts < 65 years (OR, 1.25; 95%CI, 0.50-3.14)		#Major bleeding was not significantly increased in pts < 65 years (OR, 1.25; 95%CI, 0.50-3.14)
	#Thrombolysis was associated with a lower risk of recurrent PE (OR, 0.40; 95%CI, 0.22-0.74; 1.17%[12/1024] vs 3.04%[31/1019];NNT=54		#Thrombolysis was associated with a lower risk of recurrent PE (OR, 0.40; 95%CI, 0.22-0.74; 1.17%[12/1024] vs 3.04%[31/1019];NNT=54


	===Subgroup analysis===		===Subgroup analysis===
	#Intermediate-risk PE: thrombolysis was associated with lower mortality (OR, 0.48; 95%CI, 0.25-0.92) and more major bleeding events (OR, 3.19; 95%CI, 2.07-4.92).		#Intermediate-risk PE: thrombolysis was associated with lower mortality (OR, 0.48; 95%CI, 0.25-0.92) and more major bleeding events (OR, 3.19; 95%CI, 2.07-4.92).


	==Criticisms & Further Discussion==		==Criticisms & Further Discussion==
	#There are still very few patients (n=2115) included in RCT assessing impact of thrombolysis in PE to conclude with assurance about benefit or harm. Need exists for adequately powered study.		#There are still very few patients (n=2115) included in RCT assessing impact of thrombolysis in PE to conclude with assurance about benefit or harm. Need exists for adequately powered study.

Rossdonaldson1: /* See Also */

2018-12-18T18:48:59Z

Panosiaa: /* Inclusion Criteria */

2017-07-05T20:19:35Z

Inclusion Criteria

← Older revision		Revision as of 20:19, 5 July 2017
Line 31:		Line 31:

	===Inclusion Criteria===		===Inclusion Criteria===
			Relevant articles that had a randomized controlled design in "patients with Pulmonary Embolism" that evaluated "thrombolytic therapy" as an intervention with a comparator group that included agents: low-molecular-weight heparin (LMWH), vitamin K antagonist, fondaparinux, or unfractionated heparin; and reporting of "mortality outcome"

	===Exclusion Criteria===		===Exclusion Criteria===

Ostermayer at 21:06, 29 November 2014

2014-11-29T21:06:24Z

← Older revision		Revision as of 21:06, 29 November 2014
Line 11:		Line 11:
	\| pages= 2414-21		\| pages= 2414-21
	\| pmid= 24938564		\| pmid= 24938564
	\| fulltexturl=		\| fulltexturl= http://unmhospitalist.pbworks.com/w/file/fetch/82297066/joi140068.pdf
	\| pdfurl=		\| pdfurl=http://unmhospitalist.pbworks.com/w/file/fetch/82297066/joi140068.pdf
	}}		}}
	==Clinical Question==		==Clinical Question==

Ostermayer: Ostermayer moved page Thrombolysis in Pulmonary Embolism Metanalysis to EBQ:Thrombolysis in Pulmonary Embolism Metanalysis: EBQ namespace reclassification

2014-11-29T21:02:17Z

Ostermayer moved page Thrombolysis in Pulmonary Embolism Metanalysis to EBQ:Thrombolysis in Pulmonary Embolism Metanalysis: EBQ namespace reclassification

← Older revision	Revision as of 21:02, 29 November 2014
(No difference)

Ostermayer at 21:01, 29 November 2014

2014-11-29T21:01:48Z

← Older revision		Revision as of 21:01, 29 November 2014
Line 10:		Line 10:
	\| issue=23		\| issue=23
	\| pages= 2414-21		\| pages= 2414-21
	\| pmid= ~~[http://www.ncbi.nlm.nih.gov/pubmed/~~24938564 ~~24938564]~~		\| pmid= 24938564
	\| fulltexturl=		\| fulltexturl=
	\| pdfurl=		\| pdfurl=

← Older revision		Revision as of 18:48, 18 December 2018
Line 61:		Line 61:

	==See Also==		==See Also==
			*[[Thrombolysis for PE]]
	{{Thrombolysis Submassive PE Trials}}		{{Thrombolysis Submassive PE Trials}}

← Older revision		Revision as of 19:16, 18 December 2018
Line 41:		Line 41:
	Primary: all-cause mortality and major bleeding		Primary: all-cause mortality and major bleeding
	Secondary: risk of recurrent embolism and intracranial hemorrhage (ICH).		Secondary: risk of recurrent embolism and intracranial hemorrhage (ICH).

	===Primary Outcome===		===Primary Outcome===
	~~#mortality~~ thrombolysis vs. anticoagulants (OR, 0.53; 95%CI, 0.32-0.88; 2.17% [23/1061] vs 3.89% [41/1054];NNT=59		*Mortality thrombolysis vs. anticoagulants (OR, 0.53; 95%CI, 0.32-0.88; 2.17% [23/1061] vs 3.89% [41/1054];NNT=59

	===Secondary Outcomes===		===Secondary Outcomes===
	#major bleeding (OR, 2.73; 95%CI, 1.91-3.91; 9.24% [98/1061] vs 3.42%[36/1054]; NNH=18		*major bleeding (OR, 2.73; 95%CI, 1.91-3.91; 9.24% [98/1061] vs 3.42%[36/1054]; NNH=18
	#ICH (OR, 4.63; 95%CI, 1.78-12.04; 1.46%[15/1024] vs 0.19% [2/1019]; NNH=78		*ICH (OR, 4.63; 95%CI, 1.78-12.04; 1.46%[15/1024] vs 0.19% [2/1019]; NNH=78
	#Major bleeding was not significantly increased in pts < 65 years (OR, 1.25; 95%CI, 0.50-3.14)		*Major bleeding was not significantly increased in pts < 65 years (OR, 1.25; 95%CI, 0.50-3.14)
	#Thrombolysis was associated with a lower risk of recurrent PE (OR, 0.40; 95%CI, 0.22-0.74; 1.17%[12/1024] vs 3.04%[31/1019];NNT=54		*Thrombolysis was associated with a lower risk of recurrent PE (OR, 0.40; 95%CI, 0.22-0.74; 1.17%[12/1024] vs 3.04%[31/1019];NNT=54

	===Subgroup analysis===		===Subgroup analysis===
	#Intermediate-risk PE: thrombolysis was associated with lower mortality (OR, 0.48; 95%CI, 0.25-0.92) and more major bleeding events (OR, 3.19; 95%CI, 2.07-4.92).		*Intermediate-risk PE: thrombolysis was associated with lower mortality (OR, 0.48; 95%CI, 0.25-0.92) and more major bleeding events (OR, 3.19; 95%CI, 2.07-4.92).

	==Criticisms & Further Discussion==		==Criticisms & Further Discussion==
	#There are still very few patients (n=2115) included in RCT assessing impact of thrombolysis in PE to conclude with assurance about benefit or harm. Need exists for adequately powered study.		#There are still very few patients (n=2115) included in RCT assessing impact of thrombolysis in PE to conclude with assurance about benefit or harm. Need exists for adequately powered study.